TrialPLoS medicine2020

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

Fatima Laher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.